The regulatory change—accurately stated
Since 1 July 2023, specifically authorised psychiatrists can access MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression under the TGA Authorised Prescriber pathway. The products are not ordinary take-home prescriptions, and the substances remain prohibited for other indications outside permitted research pathways.
It is therefore imprecise to say Australia simply “approved psychedelics”. Access is indication-specific, prescriber-specific and protocol-driven. The TGA states that products containing MDMA or psilocybin supplied through this pathway are unapproved therapeutic goods and have not been evaluated for inclusion on the Australian Register of Therapeutic Goods.
Treatment is more than the substance
The relevant intervention is psychedelic-assisted psychotherapy delivered within a controlled protocol. Screening, preparation, supervised administration, monitoring and integration are part of the safety model. The person’s psychiatric history, cardiovascular risk, concurrent medicines and vulnerability to psychosis or mania can be material.
For an injured person with PTSD or treatment-resistant depression, referral suitability is a treating-psychiatrist question. A medication evidence review can instead examine the existing treatment history, adverse effects, apparent treatment resistance, interactions and the accuracy of claims made about access or prognosis.
What the evidence can contribute to a legal matter
Emerging evidence may be relevant to future treatment arguments, but possibility is not the same as reasonable necessity or probable benefit. A report should distinguish clinical-trial outcomes from real-world access, identify the approved indication, describe uncertainty and avoid assuming a claimant will qualify for a program.
Costs may extend beyond the medicine to psychiatric assessment, psychotherapy sessions, monitoring and the treatment setting. Any future-needs estimate should be anchored to an actual proposed protocol rather than a headline about regulatory change.
A disciplined evidence position
The appropriate tone is neither dismissal nor hype. These therapies may offer benefit for carefully selected patients with serious conditions who have not responded to established care. They also remain tightly controlled, resource-intensive and supported by a developing evidence base. That is exactly why a transparent, source-linked opinion matters.
References
Primary and authoritative sources
Source links were checked on 25 September 2026. Laws, clinical guidance and individual evidence can change.
Frequently asked questions
A question worth testing?
Turn the medication history into a clear evidence pathway.
Start with a privacy-safe summary. We will confirm whether the matter is suitable, what records are needed and the scope of any opinion.